Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 54Lymphoma, Mantle-Cell 31Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 14Lymphoma 11Leukemia, B-Cell 7Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Leukemia 5Waldenstrom Macroglobulinemia 4Recurrence 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Prolymphocytic 2Pyloric Stenosis, Hypertrophic 1Part1: Advanced B-cell Malignancies 1Neuritis 1Neoplasms 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Glioblastoma 1DLBCL 1Chromosome 17 deletion 1

Interventions

Standard of Care 3COH04S1 COVID-19 vaccine 2remdesivir 1palbociclib 1ogalvibart 1crexavibart 1cilgavimab and tixagevimab drug combination 1acalabrutinib 1XAV-19 1Therapeutics 1Surveys and Questionnaires 1Specimen Handling 1Rabeprazole 1Prednisone 1Methylprednisolone 1IBIO123 1Glucocorticoids 1Gelsolin 1Dexamethasone 1CVnCoV COVID-19 vaccine 1COVID-19 Vaccines 1COVID-19 Serotherapy 1Atorvastatin 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 11-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
COVID-19 × acalabrutinib × Lymphoid × Clear all
NCT04564040 2020-12-29

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

AstraZeneca

Phase 1 Completed
20 enrolled
Lymphoid

COVID-19, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡